RxDoctor Payments Data

William Crigler, MD

Family Medicine · Lexington, SCNPI 1043264765

Payments from drug & device makers

$16,721in general payments, 2019–2025

Across 1,129 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$720
  • Amgen$717
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,62699%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca99$1,893
AbbVie(2 entities)159$1,560
Novo Nordisk100$1,341
Pfizer85$1,278
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC46$720
Amgen54$717
Astellas Pharma US Inc37$630
Amarin Pharma, Inc.42$609
Lilly USA, LLC44$558
Bayer29$531
Kowa Pharmaceuticals America, Inc.43$527
Abbott29$524
Boehringer Ingelheim35$517
Novartis32$464
Johnson & Johnson24$388
Otsuka America Pharmaceutical, Inc.15$340
Azurity Pharmaceuticals, Inc.21$313
Exact Sciences18$293
GSK20$277
Merck17$241
Teva Pharmaceuticals USA, Inc.14$234
Biohaven Pharmaceutical Holding Company Ltd.13$216
Esperion Therapeutics, Inc.11$214
Sumitomo Pharma America, Inc.9$196
Arbor Pharmaceuticals, Inc.14$190
Sanofi-aventis U.S. LLC11$170
Upsher-smith Laboratories LLC11$157
Eisai Inc.10$152
Antares Pharma, Inc.8$150
Takeda Pharmaceuticals U.S.A., Inc.11$147
Phathom Pharmaceuticals, Inc.9$135
Xeris Pharmaceuticals, Inc.7$124
Biohaven Pharmaceuticals, Inc.6$106
Lundbeck LLC5$93
Renalytix AI, Inc.4$80
Axsome Therapeutics, Inc.4$77
Dexcom, Inc.3$62
Inari Medical, Inc.1$44
Acerus Pharmaceuticals Corporation3$42
Harmony Biosciences LLC2$34
Ironwood Pharmaceuticals, Inc2$26
Insulet Corporation1$26
Boston Scientific1$22
Alnylam Pharmaceuticals Inc.1$21
Clarus Therapeutics Inc.2$20
Sunovion Pharmaceuticals Inc.1$19
Genentech USA, Inc.1$19
Paratek Pharmaceuticals, Inc.1$18
Halozyme Inc1$17
Bausch Health US, LLC1$17
Zyla Life Sciences, Inc.1$16
Tolmar, Inc.1$16
Almatica Pharma LLC1$16
Scynexis, Inc.1$16
E.r. Squibb & Sons, L.L.C.1$15
Idorsia Pharmaceuticals US Inc1$15
Abiomed1$14
Corcept Therapeutics1$14
Edwards Lifesciences1$14
IBSA Pharma Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,721 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$142,833
Medicare patients
313
Services billed
4,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$67,637
EliquisApixaban51$50,519
JardianceEmpagliflozin52$44,300
FarxigaDapagliflozin Propanediol41$39,356
TrulicityDulaglutide25$32,219
MounjaroTirzepatide23$29,342
JanuviaSitagliptin Phosphate44$28,714
LinzessLinaclotide30$26,609
MyrbetriqMirabegron29$26,021
UbrelvyUbrogepant11$16,013
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$14,992
Emgality PenGalcanezumab-Gnlm19$12,759
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,217
EdecrinEthacrynic Acid12$8,531
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,341$67,63762 claims
Lilly USA, LLCTrulicity, Mounjaro$558$61,56148 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,893$50,57359 claims
PfizerEliquis$1,278$50,51951 claims
Boehringer IngelheimJardiance$517$44,30052 claims
AbbVieLinzess, Ubrelvy$1,560$42,62241 claims
MerckJanuvia$241$28,71444 claims
Astellas Pharma US IncMyrbetriq$630$26,02129 claims
Bausch Health US, LLCEdecrin$17$8,53112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →